S A Factor

Summary

Affiliation: Albany Medical College
Country: USA

Publications

  1. ncbi request reprint Longitudinal outcome of Parkinson's disease patients with psychosis
    S A Factor
    Albany Medical Center, NY 12205, USA
    Neurology 60:1756-61. 2003
  2. ncbi request reprint The natural history of the syndrome of primary progressive freezing gait
    Stewart A Factor
    Parkinson s Disease and Movement Disorder Center of Albany Medical Center, 215 Washington Ave Extension, Albany, NY 12203, USA
    Arch Neurol 59:1778-83. 2002
  3. ncbi request reprint Dystonia in AIDS: report of four cases
    Stewart A Factor
    Albany Medical Center, Department of Neurology, Albany, New York 12205, USA
    Mov Disord 18:1492-8. 2003
  4. ncbi request reprint Threatening auditory hallucinations and Cotard syndrome in Parkinson disease
    Stewart A Factor
    Parkinson s Disease and Movement Disorders Center of Albany Medical Center, New York 12205, USA
    Clin Neuropharmacol 27:205-7. 2004
  5. ncbi request reprint Parkinson's disease: the treatment of drug-induced hallucinations and psychosis
    E S Molho
    Parkinson s Disease and Movement Disorder Center, Albany Medical Center, 215 Washington Ave Extension, Albany, NY 12203, USA
    Curr Neurol Neurosci Rep 1:320-8. 2001
  6. ncbi request reprint Focal myopathy as a cause of anterocollis in Parkinsonism
    N S Lava
    Albany Medical College, Department of Neurology, Albany, New York, USA
    Mov Disord 16:754-6. 2001
  7. ncbi request reprint A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events
    R B Dewey
    Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9036, USA
    Arch Neurol 58:1385-92. 2001
  8. pmc A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2
    D M Kay
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
    Neurology 75:1189-94. 2010
  9. ncbi request reprint Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease
    S A Factor
    Department of Neurology, Albany Medical Center, Albany, New York 12203, USA
    Clin Neuropharmacol 24:295-9. 2001
  10. pmc Secondary blepharospasm associated with structural lesions of the brain
    M A Khooshnoodi
    Department of Neurology, Emory University, Atlanta, GA, USA
    J Neurol Sci 331:98-101. 2013

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Longitudinal outcome of Parkinson's disease patients with psychosis
    S A Factor
    Albany Medical Center, NY 12205, USA
    Neurology 60:1756-61. 2003
    ....
  2. ncbi request reprint The natural history of the syndrome of primary progressive freezing gait
    Stewart A Factor
    Parkinson s Disease and Movement Disorder Center of Albany Medical Center, 215 Washington Ave Extension, Albany, NY 12203, USA
    Arch Neurol 59:1778-83. 2002
    ..However, confusion remains about its clinical presentation, natural history, and classification...
  3. ncbi request reprint Dystonia in AIDS: report of four cases
    Stewart A Factor
    Albany Medical Center, Department of Neurology, Albany, New York 12205, USA
    Mov Disord 18:1492-8. 2003
    ..When dystonia is seen in AIDS patients, its pattern may be a clue to the ultimate cause...
  4. ncbi request reprint Threatening auditory hallucinations and Cotard syndrome in Parkinson disease
    Stewart A Factor
    Parkinson s Disease and Movement Disorders Center of Albany Medical Center, New York 12205, USA
    Clin Neuropharmacol 27:205-7. 2004
    ....
  5. ncbi request reprint Parkinson's disease: the treatment of drug-induced hallucinations and psychosis
    E S Molho
    Parkinson s Disease and Movement Disorder Center, Albany Medical Center, 215 Washington Ave Extension, Albany, NY 12203, USA
    Curr Neurol Neurosci Rep 1:320-8. 2001
    ..Although quetiapine appears to be the best current choice, none of these medications have equaled clozapine's ability to safely treat drug-induced psychosis without the risk of worsening parkinsonism...
  6. ncbi request reprint Focal myopathy as a cause of anterocollis in Parkinsonism
    N S Lava
    Albany Medical College, Department of Neurology, Albany, New York, USA
    Mov Disord 16:754-6. 2001
    ..quot; Parkinsonian patients presenting with disproportionate anterocollis should be evaluated for focal myopathy, as this may represent one possible cause...
  7. ncbi request reprint A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events
    R B Dewey
    Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9036, USA
    Arch Neurol 58:1385-92. 2001
    ..CONCLUSION: Apomorphine by intermittent subcutaneous injection is effective and safe for outpatient use to reverse off-state events that occur despite optimized oral therapy...
  8. pmc A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2
    D M Kay
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
    Neurology 75:1189-94. 2010
    ....
  9. ncbi request reprint Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease
    S A Factor
    Department of Neurology, Albany Medical Center, Albany, New York 12203, USA
    Clin Neuropharmacol 24:295-9. 2001
    ..However, the risks associated with this drug, particularly hepatic injury, and the requirement for rigorous blood monitoring, need to be considered when choosing an appropriate treatment for patients with advanced PD...
  10. pmc Secondary blepharospasm associated with structural lesions of the brain
    M A Khooshnoodi
    Department of Neurology, Emory University, Atlanta, GA, USA
    J Neurol Sci 331:98-101. 2013
    ..Dysfunction of the basal ganglia traditionally is presumed to be the main cause of most forms of dystonia, but a growing body of evidence suggests that a network of additional cortical and subcortical structures may be involved...
  11. pmc A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease
    E M Hill-Burns
    Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, NY, USA
    Pharmacogenomics J 13:530-7. 2013
    ..Taken together, cross-validating evidence from humans and Drosophila suggests SV2C is involved in PD pathogenesis and it might be a useful marker for pharmacogenomics studies involving nicotine. ..
  12. pmc Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology
    E M Cheng
    Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA
    Neurology 75:2021-7. 2010
    ..The American Academy of Neurology (AAN) identified the need for neurologists to develop measures of neurologic care and to establish a process to accomplish this...
  13. ncbi request reprint The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia
    Sujana Reddy
    Department of Psychiatry, Albany Medical Center, Albany, New York 12205, USA
    Mov Disord 17:676-81. 2002
    ..We conclude that quetiapine is effective in improving psychosis in approximately 80% of PD patients both with and without dementia. Patients with dementia seem to have a higher propensity for worsening of motor symptoms...
  14. ncbi request reprint Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
    Joseph H Friedman
    Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island 02886, USA
    Mov Disord 21:2078-81. 2006
    ..While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising...
  15. ncbi request reprint Risperidone and Parkinson's disease
    Stewart A Factor
    Mov Disord 17:221-2. 2002
  16. ncbi request reprint Diabetes mellitus among parkinsonian patients treated chronically with clozapine
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    Parkinsonism Relat Disord 10:439-41. 2004
    ..3% for ages > or = 60 years). In this small study, parkinsonian patients on long-term, low dose clozapine were not at increased risk for developing DM. Larger controlled prospective studies are needed to confirm this...
  17. ncbi request reprint Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases
    Marjorie A Murphy
    Department of Ophthalmology, Rhode Island Hospital, Brown Medical School MAM, RI 02903, USA
    J Clin Neurosci 12:941-5. 2005
    ..We describe three cases diagnosed during life as PSP but found to have another neurologic disorder at autopsy. No explanation for the gaze palsies was found in any case...
  18. pmc Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease
    Carolyn M Hutter
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Eur J Neurol 15:134-9. 2008
    ..Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease...
  19. ncbi request reprint Progressive supranuclear palsy
    Christine D Esper
    Department of Neurology Emory University School of Medicine, Atlanta, GA, USA
    Rev Neurol Dis 4:209-16. 2007
    ..Although there are no treatments that alter the natural history of disease in PSP and no drugs that provide significant symptomatic benefits, several supportive measures are available...
  20. doi request reprint Exploring gene-environment interactions in Parkinson's disease
    Colin C McCulloch
    Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA
    Hum Genet 123:257-65. 2008
    ..The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk...
  21. doi request reprint Current status of symptomatic medical therapy in Parkinson's disease
    Stewart A Factor
    Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, Georgia 30329, USA
    Neurotherapeutics 5:164-80. 2008
    ..The article closes with a discussion of future directions and new drugs under development...
  22. doi request reprint Genetic association between alpha-synuclein and idiopathic Parkinson's disease
    Denise M Kay
    New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008
    ..1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P = 0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD...
  23. ncbi request reprint Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Mov Disord 17:158-61. 2002
    ..We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period...
  24. ncbi request reprint Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease
    Stewart A Factor
    Parkinson s Disease and Movement Disorders Center of Albany Medical Center, Albany, New York 12205, USA
    Neurology 62:S12-7. 2004
    ..Subutaneous intermittent bolus injects are also useful in patients post operatively who are unable to take oral medications...
  25. ncbi request reprint Failure of recognition of drug-induced parkinsonism in the elderly
    Christine D Esper
    Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    Mov Disord 23:401-4. 2008
    ..Cessation of the offending agent results in improvement of symptoms and would eliminate the need for dopaminergic agents, which are known to commonly cause side effects in the elderly...
  26. ncbi request reprint Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
    Karen M Powers
    Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
    Mov Disord 23:88-95. 2008
    ..13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated...
  27. pmc LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Am J Hum Genet 79:752-8. 2006
    ..Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas...
  28. ncbi request reprint Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics
    Denise M Kay
    Genomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA
    Mov Disord 21:519-23. 2006
    ..Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date...
  29. ncbi request reprint Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease
    Denise M Kay
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
    Genet Test 10:221-7. 2006
    ..Test results can have psychological, social, and economical ramifications; thus, proper counseling is essential...
  30. pmc Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study
    Alexis Elbaz
    INSERM, Unit 708, Paris, France
    Lancet Neurol 5:917-23. 2006
    ..Small-scale replication studies were largely non-confirmatory, but a meta-analysis that included data from the original study could not exclude all SNP associations, leaving relevance of several markers uncertain...
  31. ncbi request reprint Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation
    Stewart A Factor
    Mov Disord 22:148-9. 2007
  32. ncbi request reprint Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients
    Denise M Kay
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
    Ann Neurol 61:47-54. 2007
    ..We present a comprehensive sequence analysis of parkin in control subjects...
  33. ncbi request reprint Pharmacology of atypical antipsychotics
    Stewart A Factor
    Parkinson s Disease and Movement Disorder Center of Albany Medical Center, Albany, New York, USA
    Clin Neuropharmacol 25:153-7. 2002
  34. pmc Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family history
    Ami R Rosen
    Department of Neurology, Emory University, 1841 Clifton Rd, Atlanta, GA 30329, USA
    Neurogenetics 8:263-70. 2007
    ..These findings suggest the existence of common genetic and/or environmental factors that predispose to both AD and PD in the subset of cases with positive family history of both neurodegenerative diseases...
  35. pmc Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Ann Neurol 62:137-44. 2007
    ..We sought to replicate these findings...